All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Multiple Myeloma (MM) is a highly heterogeneous disease, with huge variations in life expectancy and varying prognoses, that appear to depend on a huge number of variables such as patient age, general health and a range of biomarkers. Patients are now classified at diagnosis using the Revised International Staging System (RISS), a stratification tool that takes into account a number of prognostic factors, including the presence of chromosomal abnormalities known to dictate a poor prognosis, as well as serum biomarkers. However, whilst this classification appears to help identify groups of patients with a distinct outcome and stratify patients according to expected treatment responses, there is still a need for more robust prognostic indicators that are potentially independent of other factors.
A research group in Cardiff University School of Medicine, led by Duncan Baird, have been examining the prognostic capacity of high-resolution telomere analysis, combined with a functional definition of telomere length, in a range of cancers. In a study published in the British Journal of Haematology, Sam Hyatt and Rhiannon E. Jones applied this technology to MM, and found that short telomere length strongly correlated with shorter Overall Survival (OS).
In conclusion, the prognostic power of a previously determined length threshold for telomere dysfunction gave a HR of 3.4, which is highly prognostic for OS in MM. This is a striking correlation given the use of unsorted cells, and therefore measurements in sorted cell samples could be even more striking. This technique could add further prognostic power to current risk assessments. Professor Duncan Baird who led the study said, “The next step is to assess telomere length in larger studies to establish how it can be integrated into existing assessments that predict patient outcome.” Patients with MM face a huge degree of uncertainty, but this finding is an exciting step forward. This relatively simple blood test could be developed for routine use in order to more accurately predict disease progression, and ultimately direct tailored treatment regimens.
The variable clinical outcomes of Multiple Myeloma (MM) patients are incompletely defined by current prognostication tools. We examined the clinical utility of high-resolution telomere length analysis as a prognostic marker in MM. Cohort stratification, using a previously determined length threshold for telomere dysfunction, revealed that patients with short telomeres had a significantly shorter overall survival (P < 0·0001; HR = 3·4). Multivariate modelling using forward selection identified International Staging System (ISS) stage as the most important prognostic factor, followed by age and telomere length. Importantly, each ISS prognostic subset could be further risk-stratified according to telomere length, supporting the inclusion of this parameter as a refinement of the ISS.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox